Kalaris Reinforces TH103’s Potential in Wet AMD Ahead of 2027 Catalyst

Kalaris reports 6-month follow-up data from 20 patients in TH103 Phase 1a trial. 29% of treatment-naïve patients remained injection-free for 6 months. Phase 1b/2 data expected H1 2027.